Navigation Links
Aton Pharma Announces Distribution Partnership in the Asia Pacific Region
Date:5/21/2008

LAWRENCEVILLE, N.J., May 21 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that it has signed a marketing and distribution agreement with PharmaLink Asia Pacific Pte. Ltd. to enable Aton to expand distribution into several countries in Asia and Australia.

"This partnership marks an important milestone for Aton as we execute our mission to expand access to our medically essential portfolio of products," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "PharmaLink is uniquely qualified to help us expand our reach into the Asia Pacific region."

"Aton has a portfolio of unique products, and we are excited to partner with them to serve patients who rely on the availability of these medicines," stated Dr. George Eassey, VP of PharmaLink Asia Pacific. "We look forward to a long and successful partnership with Aton."

PharmaLink is a subsidiary of the INVIDA group and a leading provider of pharmaceutical and healthcare marketing and sales services in the Asia Pacific region. PharmaLink's strong presence, with subsidiaries across Asia Pacific and associates representing 13 countries within the region, as well as the company's in-depth understanding of these markets, enables PharmaLink to enhance the potential of clients' brands and products.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under-treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see http://www.atonrx.com.

About Invida Pharmaceutical Holdings Pte. Ltd.

Invida Pharmaceutical Holdings Pte. Ltd. is a specialty pharmaceutical company and the parent of PharmaLink, which is the leading pharmaceutical and healthcare commercialization services provider in Asia Pacific; and Inovail, an independently-managed, specialty pharmaceutical company focused on market-driven innovation in the areas of dermatology, complementary oncology and female healthcare. Headquartered in Singapore, Invida's focus is in the Asia Pacific region, where it has offices in 13 countries. Its shareholders include Temasek Holdings, Quintiles Transnational and the Zuellig Group. More information about Invida can be found at http://www.invida.com.


'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
2. Nebulized Formoterol Fumarate Has Comparable Pharmacokinetic and Pharmacodynamic Profile to Dry Powder Formulation
3. TIBCO Spotfire Puts the Spotlight on Screening at InfoTech for Pharma and Biotech
4. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
5. Pharmaxis Aridol Authorised for Sale in Germany
6. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
7. China Pharma Holdings, Inc. Donates Medicine for Sichuan Earthquake Relief
8. MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
9. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
10. KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R)
11. Transdel Pharmaceuticals Closes $4 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):